ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Vertex Pharmaceuticals and Sun Pharmaceutical Industries side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

Vertex PharmaceuticalsSun Pharmaceutical Industries
studies on the registry295328
open to participants now2011
phase 3 studies under way229
reach primary completion within a year215
programswith a study of their own in two years1814

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseVertex PharmaceuticalsSun Pharmaceutical Industries
Phase 1

Vertex Pharmaceuticals: 4 of its 18 programs at phase 1

  1. VX-581phase 1
  2. VX-272phase 1
  3. VX-433phase 1
  4. VX-828phase 1
22%

Sun Pharmaceutical Industries: 10 of its 14 programs at phase 1

  1. DL2phase 1
  2. DL3phase 1
  3. DL4phase 1
  4. DL5phase 1
  5. Dose level (DL)1phase 1

and 5 more — sign in to see them all

71%
Phase 2

Vertex Pharmaceuticals: 4 of its 18 programs at phase 2

  1. VX-407phase 2
  2. VX-670phase 2
  3. VX-993phase 2
  4. SSTR2-targeting Non-peptide Drug Conjugate CRN09682phase 2
22%

Sun Pharmaceutical Industries: 1 of its 14 programs at phase 2

  1. utreglutidephase 2
7%
Phase 3

Vertex Pharmaceuticals: 8 of its 18 programs at phase 3

  1. povetaciceptphase 3
  2. tezacaftorphase 3
  3. atumelnantphase 3
  4. Paltusotinephase 3
  5. inaxaplinphase 3

and 3 more — sign in to see them all

44%

Sun Pharmaceutical Industries: 2 of its 14 programs at phase 3

  1. Deuruxolitinibphase 3
  2. Reformulated Levulan Kerastick containing aminolevulinic acid hydrochloride (ALA HCl), 20%phase 3
14%
Approved, new studies

Vertex Pharmaceuticals: 2 of its 18 programs at approved, new studies

  1. ivacaftorapproved, new study
  2. suzetrigineapproved, new study
11%

Sun Pharmaceutical Industries: 1 of its 14 programs at approved, new studies

  1. Phenobarbitalapproved, new study
7%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Vertex Pharmaceuticals12 readouts · 5 phase 3·

Vertex Pharmaceuticals, Dec ’26: 1 program whose next study reaches primary completion

  1. VX-407phase 2 · Dec 15 · NCT07868926

Vertex Pharmaceuticals, Jan ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. suzetrigineapproved, new study · Jan 25 · NCT06696443

Vertex Pharmaceuticals, Feb ’27: 1 program whose next study reaches primary completion

  1. VX-670phase 2 · Feb 2 · NCT06185764

Vertex Pharmaceuticals, Mar ’27: 2 programs whose next study reaches primary completion

  1. VX-433phase 1 · Mar 5 · NCT07584434
  2. VX-993phase 2 · Mar 25 · NCT06619860

Vertex Pharmaceuticals, Apr ’27: 2 programs whose next study reaches primary completion, 2 in phase 3

  1. ivacaftorapproved, new study · Apr 6 · NCT05331183
  2. tezacaftorphase 3 · Apr 6 · NCT05331183

Vertex Pharmaceuticals, May ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. atumelnantphase 3 · May 0 · NCT07144163

Vertex Pharmaceuticals, Jun ’27: 1 program whose next study reaches primary completion

  1. VX-272phase 1 · Jun 26 · NCT07437105

Vertex Pharmaceuticals, Jul ’27: 1 program whose next study reaches primary completion

  1. VX-581phase 1 · Jul 12 · NCT07283770

Vertex Pharmaceuticals, Aug ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. Paltusotinephase 3 · Aug 0 · NCT07087054
  2. SSTR2-targeting Non-peptide Drug Conjugate CRN09682phase 2 · Aug 0 · NCT07129252
··
Sun Pharmaceutical Industries4 readouts · 2 phase 3·

Sun Pharmaceutical Industries, Dec ’26: 1 program whose next study reaches primary completion

  1. Drugs, Investigationalphase 1 · Dec 0 · NCT07729579

Sun Pharmaceutical Industries, Jan ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. Reformulated Levulan Kerastick containing aminolevulinic acid hydrochloride (ALA HCl), 20%phase 3 · Jan 0 · NCT07144345
··

Sun Pharmaceutical Industries, Apr ’27: 1 program whose next study reaches primary completion

  1. utreglutidephase 2 · Apr 0 · NCT07282743

Sun Pharmaceutical Industries, May ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. Deuruxolitinibphase 3 · May 0 · NCT03898479
·····
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 22, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Vertex Pharmaceuticals

New programs 0

None

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 4

Sun Pharmaceutical Industries

New programs 1

  • Phenobarbitalapproved, new study · first study · Oct 13 · Seizures

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

Where they overlap

Conditions where at least two of them have programs: 2 in all. A program counts in each condition its studies name most.

ConditionVertex PharmaceuticalsSun Pharmaceutical Industries
COVID-19both · compare here

Vertex Pharmaceuticals in COVID-19: 1 program

  1. Biological Productsphase 3

Their studies: Vertex Pharmaceuticals’ studies of COVID-19 in search

Sun Pharmaceutical Industries in COVID-19: 1 program

  1. Ivermectinphase 1

Their studies: Sun Pharmaceutical Industries’ studies of COVID-19 in search

Renal Insufficiencyboth · compare here

Vertex Pharmaceuticals in Renal Insufficiency: 1 program

  1. inaxaplinphase 3

Their studies: Vertex Pharmaceuticals’ studies of Renal Insufficiency in search

Sun Pharmaceutical Industries in Renal Insufficiency: 1 program

  1. Deuruxolitinibphase 3

Their studies: Sun Pharmaceutical Industries’ studies of Renal Insufficiency in search

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

No gene two of them both target, among the programs whose target is known.

A target, or a pathogen for a vaccine, known for: Vertex Pharmaceuticals 6 of 18 · Sun Pharmaceutical Industries 3 of 14 programs (8 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.